INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...
INDIANAPOLIS, June 15, 2021 /PRNewswire/ -- To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to ...
TORONTO, Oct. 2, 2019 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce the availability of Emgality™ (galcanezumab) in Canada. Emgality is indicated for the prevention of migraine ...
Eli Lilly and Company LLY announced that the FDA has approved its calcitonin gene-related peptide (CGRP) antibody, Emgality (galcanezumab), for the preventive treatment of migraine in adults. The drug ...
INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...
INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...
The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback